A composition based on ubidecarenone, or coenzyme Q10 or CoQ10, comprises CoQ10, one or more specific hydrophylic carriers selected from the maltodextrins class and one or more adjuvant agents selected from the sucrose-esters class.

The disclosure is generally directed to methods and compositions for reducing blood cholesterol levels, and more particularly to dietary supplements for reducing blood cholesterol levels. The dietary supplements for reducing cholesterol typically comprise at least one phytosterol source, at least one soluble fiber source, at least one guggulsterone source, and at least one policosanol source.

The disclosure is generally directed to methods and compositions for reducing blood cholesterol levels, and more particularly to dietary supplements for reducing blood cholesterol levels. The dietary supplements for reducing cholesterol typically comprise at least one phytosterol source, at least one soluble fiber source, at least one guggulsterone source, and at least one policosanol source.

Flavored chewable wafers containing caffeine suitable for increasing alertness and allow an individual to perform tasks in a more focused and energetic manner comprises, formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients.

Flavored chewable wafers containing caffeine suitable for increasing alertness and allow an individual to perform tasks in a more focused and energetic manner comprises, formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients.

The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the CSF and interstitial fluids in the brain.

The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the CSF and interstitial fluids in the brain.

The present technology relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present technology relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, sleep apnea. Methods of using the composition/formulation to elicit enhanced sleep quality, induce short duration sleep and/or treat sleep disorders are also provided.

The present technology relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present technology relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, sleep apnea. Methods of using the composition/formulation to elicit enhanced sleep quality, induce short duration sleep and/or treat sleep disorders are also provided.